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Abstract
Introduction: Single nucleotide polymorphisms (SNP) in the 
fat mass and obesity-associated (FTO) gene have been asso-
ciated with type 2 diabetes (T2D) and its complications. The 
aim of the present research was to investigate which and 
how (directly or indirectly) clinical and metabolic variables 
mediate the association between fat mass and the FTO gene 
and early chronic kidney disease (CKD) in individuals with 
T2D. Methods: This cross-sectional study was conducted in 
a sample of 236 participants with T2D (53.4% women, mean 
age 60 ± 10 years). DNA samples were genotyped for the 
rs7204609 polymorphism (C/T) in the FTO gene. Clinical, an-
thropometric, and metabolic data were collected. Path anal-
ysis was used to evaluate the associations. Results: Of the 
sample, 78 individuals with T2D had CKD (33%). Presence of 
the risk allele (C) was higher among participants with CKD 
(21.8 vs. 10.8%; p = 0.023). This polymorphism was positively 
associated with higher waist circumference, which in turn 
was associated with higher glycated hemoglobin and higher 
blood pressure. A higher blood-pressure level was associat-
ed with higher urinary albumin excretion (UAE) and as ex-
pected, higher UAE was associated with CKD. Path analysis 
showed an indirect relationship between the FTO gene and 
early CKD, mediated by waist circumference, blood-pressure 
levels, and UAE. Conclusions: These findings suggest that 
the C allele may contribute to genetic susceptibility to CKD 
in individuals with T2D through the presence of central obe-
sity, hypertension, and high albuminuria.
© 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Diabetes is a metabolic disorder characterized by sus-
tained hyperglycemia. This is one of the main factors re-
sponsible for the development and progression of diabe-
tes-associated chronic microvascular damage, which in-
cludes chronic kidney disease (CKD) [1]. According to 
the literature, CKD occurs in 20–40% of individuals with 
diabetes and is one of its most prevalent complications 
[1–4].
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Type 2 diabetes (T2D) accounts for 90–95% of all dia-
betes [1]. However, its pathogenesis and complications 
are difficult to characterize, and both environmental and 
genetic risk factors play fundamental roles in these pro-
cesses [1, 5, 6]. The relevance of genetic factors to the de-
velopment and progression of T2D has been widely in-
vestigated [7, 8].
In this sense, genome-wide association studies have 
identified an association between polymorphisms of the 
fat mass and obesity-associated (FTO) gene and T2D in 
several populations [9], as well as associations with CKD 
[10–12]. The FTO gene is located on the long arm of the 
Chromosome 16 on the position 12.2 and consists of 9 
exons, occupying an area of >400 kb [13]. The expression 
of the FTO gene is associated with regulation of food in-
take and energy balance [14, 15]. Moreover, the FTO gene 
has been linked with central obesity [16], hypertension 
[17], and poor glycemic control [18]. All of these condi-
tions are related to T2D [1] and to increased CKD rates 
[19, 20]. In Brazilians with T2D, the rs7204609 polymor-
phism of the FTO gene has been associated with high lev-
els of urinary albumin excretion (UAE), [21] an impor-
tant early clinical marker of CKD [22]. The rs7204609 
polymorphism (C/T), however, has been little investigat-
ed, and its influence on the renal function is still un-
known.
The primary objective of this study is to evaluate 
whether the polymorphism rs7204609 is associated with 
presence of CKD in individuals with T2D, and whether it 
is mediated by other conditions. We hypothesized that 
this polymorphism would influence early CKD either di-
rectly or indirectly, that is, through other clinical and 
metabolic conditions.
Materials and Methods
Patients and Study Design
This cross-sectional study was conducted in a sample of 236 
individuals with T2D (defined as age 30 years or older at the onset 
of diabetes, no history of ketoacidosis or documented ketonuria, 
and, in insulin users, initiation of insulin therapy at least 5 years 
after diagnosis).
We selected individuals according to the following criteria: 
24-h UAE < 200 μg/min, absence of urinary tract infection or oth-
er renal diseases, and absence of heart failure (New York Heart 
Association class IV). Participants with macroalbuminuria (UAE 
>200 μg/min) were not included because they are usually the sub-
ject of specific recommendations. All medications in use were 
maintained during the study. The Ethics Committee approved the 
protocol (#2015-0625), and participants gave their written in-
formed consent for participation.
This study was designed and conducted in accordance with the 
STrengthening the REporting of Genetic Association studies re-
porting recommendations, an extension of the STROBE Statement 
(online suppl. material; for all online suppl. material, see www.
karger.com/doi/10.1159/000516118).
Anthropometrical, Clinical, and Metabolic Assessment
Body weight and height of the participants (not wearing coats 
or shoes) were obtained using an anthropometric scale, with mea-
surements recorded to the nearest 100 g for weight and to the near-
est 0.1 cm for height. Body mass index (kg/m2) was calculated as 
weight (kilograms) divided by height (meters) squared. Waist cir-
cumference was measured midway between the margin of the low-
est rib and the iliac crest, near the umbilicus, using a flexible, non-
stretch fiberglass tape. Central obesity was defined by a waist cir-
cumference ≥94 cm for men and ≥80 cm for women [23].
Blood pressure was measured by the auscultatory method using 
a standard mercury sphygmomanometer (Korotkoff phases I and 
V). Two measurements were obtained, to the nearest 2 mm Hg, 
after a 10-min rest. Hypertension was defined as the blood pres-
sure >130/80 mm Hg on 2 occasions or use of antihypertensive 
drugs [1, 24].
Blood samples were obtained after a 12-h fast. Glycated hemo-
globin (HbA1c) was determined by ion-exchange high-perfor-
mance liquid chromatography (Merck-Hitachi L-9100 glycated 
hemoglobin analyzer, reference range, 4.7–6.0%; Merck, Darm-
stadt, Germany). UAE was measured by an immunoturbidimetric 
method (Microalb; Ames-Bayer, Tarrytown, NY) using urine sam-
ples with albumin concentrations of 30 and 100 mg/L. The intra-
assay and inter-assay coefficients of variation at our laboratory 
were both 6% [25].
The presence of CKD was evaluated as described elsewhere [1]. 
According to 24-h UAE results, the study participants were classi-
fied as having normoalbuminuria (UAE <20 μg/min) or microal-
buminuria (UAE >20–199 μg/min). Microalbuminuria was always 
confirmed in a second urine sample [26]. We calculated the esti-
mated glomerular filtration rate (eGFR) using the CKD-Epidemi-
ology Collaboration formula, considering creatinine levels, sex, 
race, and age [27].
Genotyping for FTO Polymorphism
Peripheral blood samples were collected from all the partici-
pants for DNA extraction. Detection of the rs7204609 FTO Single 
nucleotide polymorphism (SNP) was performed by allelic discrim-
ination assay (TaqMan SNP Genotyping Assays, Applied Biosys-
tems, CA) using the ABI PRISM 7000 Real-Time PCR System, and 
genotypes were read using automated software (SDS1.1, Applied 
Biosystems, CA). Reactions were run in 10-mL volumes using an 
amplification protocol of 95°C for 10 min, followed by 40 cycles of 
95°C for 15 s, and then 60°C for 1.5 min.
Statistical Analyses
Statistical analysis was performed in IBM SPSS® Statistics 26 
software. The unpaired Student’s t test, the Mann-Whitney U test, 
and the χ2 test were used as appropriate. Genotypes were analyzed 
using risk alleles. In the rs7204609 (C/T) polymorphism, the risk 
allele is the C allele. For analysis, all the participants with the puta-
tive C allele were pooled together (CT and CC genotypes) and 
compared with those without the C allele (TT genotypes). A χ2 test 
was also used to evaluate Hardy-Weinberg equilibrium and assess 




the frequency distribution of genotypes. The results were ex-
pressed as mean (SD), median (interquartile range), or absolute 
and relative frequency. p values <0.05 were considered statisti-
cally significant.
MPlus® software, version 5.0, was used both to analyze the re-
lationship between the presence of the C allele and CKD and to 
investigate, via the path analysis, the mediating role of selected 
variables in relationships involving the waist circumference, blood 
pressure, HbA1c, and UAE. The path analysis is a subset of struc-
tural equation modeling [28] an extension of regression analysis 
that allows simultaneous exploration of the complex relationships 
between multiple variables [29].
In the path analysis, explanatory variables may affect the out-
come variable directly or indirectly. Direct effects represent a di-
rect relationship between the 2 variables, that is, relationships 
which are not mediated by other variables in the model. They can 
be interpreted as a regression coefficient. In turn, indirect effects 
express a sequence of paths with at least 1 intermediate or mediat-
ing variable. They are calculated by multiplying the direct effects 
between the variables involved in that path. Finally, the total effect 
is calculated from the sum of direct and indirect effects between 
the 2 variables [30, 31]. Thus, in this study, the term “effect” is used 
in the sense of association not causality.
Standardized and nonstandard coefficients were estimated 
with their respective p values. Odds ratios were obtained from ex-
ponentiation of nonstandard effects. The robust maximum likeli-
hood method, which does not require the assumption of normal-
ity in multivariate data, was used to estimate the parameters [30].
Analyses of the variables associated with CKD included addi-
tional adjustments for age and sex. A selection of different mea-
sures was used to verify the fit of the model. The root mean square 
error of approximation and the standardized root mean square 
residual are both based on the model residuals; values <0.06 indi-
cate that the theoretical model fits the data [32–34]. The Tucker-
Lewis index and comparative fit index were also estimated, with 
values >0.90 indicating the good model fit [30, 32].
Results
A total of 236 individuals with T2D were enrolled in 
this study (60.1 ± 10.3 years of age; 11 [6–18] years of 
diabetes duration, 52.7% was female and 86.4% were 
white). Among them, 33% of participants had CKD. The 
mean body mass index was 28.6 ± 4.2 kg/m2 and 83.9% 
had central obesity. The medians of the HbA1c levels 
were 7.0 (6.3–8.1) percent, UAE was 6.4 (3.5–33.0) µg/
min, and the eGFR was 85 (71.2–101.0) mL/min/1.73 m2. 
Also, the hypertension was present in 88.1% in all the par-
ticipants. With regard to drug treatment, 94.9% used oral 
antihyperglycemic agents, 5.1% only diet and 55.5% used 
ACE inhibitors. Finally, the genotype frequencies of each 
Table 1. Characteristics of study participants, by the categorized presence of CKD
Variables Presence of CKD p value
no (n = 158) yes (n = 78)
Sex, n (%) 95 (75.4) 31 (24.6) 0.003**Female, n (%) 63 (57.3) 47 (42.7)
Age, years 57.5±10.8 61.3±9.9 0.008**
Duration of diabetes, years 11.0 (7.0–18.0) 10.0 (5.0–16.0) 0.147
Risk allele on rs7204609 FTO SNP, n (%) 17 (10.8) 17 (21.8) 0.023**
Central obesity, n (%)* 131 (82.7) 67 (85.9) 0.477
HbA1c, % 7.4±1.6 7.4±1.5 0.940
Diabetes treatment, n (%)
Only diet 5 (41.7) 7 (58.3)
0.009**Oral antidiabetic agents 105 (75) 35 (25)Insulin 15 (53.6) 13 (46.4)
Insulin + oral antidiabetic agents 33 (58.9) 23 (41.1)
Hypertension, n (%) 134 (64.4) 52 (66.6) 0.072
ACE inhibitors, n (%) 79 (50) 52 (66.6) 0.056
UAE (µg/min) 3.5 (3.4–8.6) 57.4 (33.6–96.3) <0.001**
eGFR (mL/min per 1.73 m2) 84.5 (71.2–98.0) 86.0 (71.5–104.2) 0.454
Data are expressed as number of patients with the characteristic (%), mean ± SD or median (25th percentile, 
75th percentile) and compared using chi-square, Student t, and Mann-Whitney U test, respectively. CKD, chron-
ic kidney disease; SNP, single nucleotide polymorphism; FTO, fat mass and obesity-associated; HbA1c, glycated 
hemoglobin; ACE, angiotensin-converting enzyme inhibitors; UAE, urinary albumin excretion; eGFR, estimated 
glomerular filtration rate. * Elevated waist circumference ≥94 cm for men and ≥80 cm for women. ** p value has 





rs7204609 allele were 85.2% for TT, 13.1% for CT, and 
1.7% for CC (online suppl. Table 1). No deviation from 
Hardy-Weinberg equilibrium was observed (χ2 = 2.739; 
p = 5.642).
Table 1 lists the study participants’ characteristics, ac-
cording to the presence of CKD. The proportion of CKD 
was higher in men and in older participants. There was a 
higher proportion of the C allele presence among indi-
viduals with CKD than among those without CKD (21.8 
vs. 10.8%; p value =0.023). More aggressive treatment of 
diabetes was more common in individuals without CKD 
than in individuals with CKD. As expected, those par-
ticipants with CKD had higher UAE levels than those 
without CKD (57.4 [33.6–96.3] vs. 3.5 [3.4–8.6]; p < 
0.001). The relation to central obesity, glycemic control, 
or the presence of hypertension was not significant.
The path analysis achieved a satisfactory fit according 
to the root mean square error of approximation (0.000), 
standardized root mean square residual (0.015), compar-
ative fit index (1.000), and Tucker-Lewis index (1.192) 
indices. Table 2 shows the direct, indirect, and total coef-
ficients for the mediation relations. The only significant 
indirect effect was observed in the relationship between 
the FTO rs7204609 polymorphism and CKD mediated by 
waist circumference, blood pressure, and UAE (p = 
0.045). Each 1 mg/min increase in UAE was associated 
with a 0.8% (CI 95% 0.7–0.9%) increase in CKD odds (on-
line suppl. Table 2).
When we analyzed the standardized coefficients for di-
rect effects in the path analysis, high UAE was, as expected, 
positively associated with CKD (p < 0.001). A positive as-
sociation was also observed between the high blood pres-
sure and high UAE (p = 0.004). The waist circumference 
was positively associated with the blood pressure (p < 
0.001) and with glycated hemoglobin (p = 0.004). The pres-
ence of the C allele in the FTO gene was associated with 
higher waist circumference values (p < 0.001) but did not 
have a significant direct effect on CKD (shown in Fig. 1).
Table 2. Direct, indirect, and total coefficients for the mediation relations
Relation Mediators Effect Standardized 
coefficient
SE p value
Risk allele on rs7204609 FTO 
SNP → CKD
Direct 0.072 0.044 0.104
UAE (µg/min) Indirect 0.022 0.036 0.543
HbA1c (%) Indirect 0.003 0.007 0.639
HbA1c (%) → UAE (µg/min) Indirect −0.001 0.002 0.636
Waist circumference → HbA1c (%) → UAE (µg/min) Indirect 0.002 0.003 0.499
Blood pressure Indirect −0.003 0.009 0.687
Blood pressure → UAE (µg/min) Indirect −0.001 0.002 0.636
Waist circumference → blood pressure → UAE (µg/min) Indirect 0.005 0.002 0.045
Total 0.087 0.061 0.153
Waist circumference → CKD HbA1c (%) Indirect −0.027 0.035 0.441
Blood pressure Indirect −0.044 0.025 0.084
HbA1c (%) → UAE (µg/min) Indirect 0.009 0.013 0.489
Blood pressure → UAE (µg/min) Indirect 0.024 0.010 0.019
Total −0.038 0.047 0.412
HbA1c (%) → CKD UAE (µg/min) Direct −0.089 0.093 0.336
Indirect 0.029 0.039 0.469
Total −0.060 0.100 0.544
Blood pressure → CKD UAE (µg/min) Direct −0.151 0.082 0.066
Indirect 0.082 0.029 0.005
Total −0.069 0.092 0.450
UAE (µg/min) → CKD Direct 0.584 0.059 0.000
Bold p values are statistically significant (p < 0.05). FTO, fat mass and obesity-associated; SNP, single nucleotide polymorphism; CKD, chronic kidney 
disease; HbA1c, glycated hemoglobin; UAE, urinary albumin excretion; SE, standard error. All variables were considered continuous, except for the presence 
of the risk allele of the rs7204609 polymorphism of the FTO gene (C allele) and for the presence of CKD.





CKD is one of the most prevalent microvascular com-
plications and occurs in 20–40% of the individuals with 
diabetes [1–4]. In fact, in our sample, 33% of participants 
had CKD. Presence of the risk allele (C) in the FTO gene 
was more frequent in these participants than those with-
out the disease (21.8 vs. 10.8%; p = 0.023). These findings 
indicate a relevant relationship between the rs7204609 
polymorphism and CKD, which, to the best of our knowl-
edge, has not been reported previously. Studies in Czech, 
Japanese, and Emirati populations have demonstrated a 
relationship between CKD and FTO variants – rs17817449, 
rs56094641, and both rs1421086 and rs17817449 poly-
morphisms, respectively [10–12].
Studying the factors that trigger CKD caused by diabe-
tes is difficult because of several issues related to the un-
derlying condition [19, 20]. Our path analysis found no 
significant direct effect of the FTO gene on CKD. How-
ever, we detected an indirect effect mediated by the central 
obesity, blood pressure, and UAE, all of which are condi-
tions or biomarkers related to the renal function [19, 20, 
35–37]. In a Chinese population, components of the met-
abolic syndrome (including central obesity and hyperten-
sion) were associated with higher UAE, a well-known pre-
dictor of CKD [38]. Although the mechanisms are not 
fully understood, central obesity in conjunction with hy-
pertension and diabetes could be responsible for increased 
endothelial permeability and intraglomerular capillary 
pressure, with consequent development of CKD [39].
Regarding the effect of genetics, in our sample, the FTO 
gene was positively associated with the waist circumfer-
ence values. This is consistent with the previous reports [7, 
8, 40] suggesting genetic susceptibility to an obesity phe-
notype in individuals with T2D. Studies have shown that 
FTO polymorphisms are associated with higher food in-
take and increased hunger/reduced satiety [41]. The FTO 
gene is highly expressed in the hypothalamus region, 
which is involved in appetite regulation [15]. However, 
there is no information about the association of energy in-
take with the rs7204609 SNP. A possibility would be re-
lated to linkage disequilibrium with another polymor-
phism in the FTO gene. In this sense, the rs7204609 poly-
morphism is in the strong linkage disequilibrium with a 
common polymorphism in the FTO gene, the rs9939069 
(D′ = 5 and r2 = 0.014; https://www.ncbi.nlm.nih.gov/
probe/docs/projhapmap/), which has been associated with 
obesity, diabetes, and metabolic syndrome [42, 43].
In addition, the role of ethnicity should be considered 
when interpreting the influence of the rs7204609 poly-
morphism on obesity, as the association between rs7204609 
and obesity has been shown to differ across different eth-
nic groups. In West Africans, for example, this polymor-
phism was positively associated with obesity, whereas in a 
Japanese population, the association was negative [44, 45].
Central obesity is a direct risk factor for deterioration 
of the renal function [35] and influences poor glycemic 
and blood-pressure control [46–48]. In our sample, higher 
waist circumference was associated with higher glycated 





































Fig. 1. Path analysis for the relationship be-
tween the FTO gene and CKD in individu-
als, with T2D. In path analysis, all variables 
were considered continuous, except for the 
presence of the risk allele of the rs7204609 
polymorphism of the FTO gene (C allele), 
diabetes treatment (4 categories: only diet, 
oral antidiabetic agents, insulin, and insulin 
+ oral antidiabetic agents) and the presence 
of CKD. Associations, with CKD, were fur-
ther adjusted for age and sex. Standardized 
coefficients and p values were used as the 
parameter estimates in path analysis. 
Dashed lines indicate paths, with statistical 
significance. ** p value <0.01. FTO, obesity-






among the leading risk factors for the development and 
progression of CKD [19, 20, 37]. Furthermore, the blood-
pressure control and glycemic control are part of thera-
peutic strategies to prevent high UAE in individuals with 
T2D [49, 50]. In our sample, participants with higher 
blood-pressure levels had higher UAE levels. Hyperten-
sion can impair vascular endothelial function, leading to 
an elevated eGFR and high UAE [37, 51].
As expected, individuals with CKD had higher UAE 
values in our analysis. In 2015, a meta-analysis found that, 
for every 30% reduction in UAE, the risk of kidney disease 
decreased by 23.7% [52]. In our study, a 1-unit increase in 
UAE was associated with a 0.8% (CI 95% 0.7–0.9%) in-
crease in the odds of CKD. We should stress that the pres-
ence of CKD was significantly more frequent among older 
and male members of our sample, which is consistent with 
the literature [53, 54].
Based on our results, we believe that changes in lifestyle, 
especially the control of obesity and blood pressure, are 
important factors in the treatment of diabetes and could 
promote vascular protection in this group of individuals. 
However, further intervention studies are needed to test 
the genetic variants of the FTO gene to confirm our find-
ings. We did not find any studies on this topic that have 
applied the path analysis as a statistical method. Our anal-
ysis of the mediating effects of waist circumference, HbA1c, 
blood pressure, and UAE on the relationship between the 
FTO gene and CKD differentiates this study from the pre-
vious research.
However, the study also has limitations. First, the small 
sample size prevents generalization of our data, but it is 
sufficient for the analyses conducted. Moreover, the medi-
ating association needs to be confirmed by further replica-
tion studies, particularly in other ethnic populations, since 
this study only enrolled individuals from the Southern 
Brazil. Second, medical conditions (such as macroalbu-
minuria and established renal disease) as exclusion criteria 
also would be a limiting factor. However, the inclusion of 
these participants would have biased the results. In addi-
tion, a positive association between diabetes treatment and 
glycemic control was demonstrated in the analysis. This 
may at least partly explain why we did not find an associa-
tion between glycemic control and CKD.
Conclusion
In this study, the FTO gene polymorphism rs7204609 
appears to contribute to genetic susceptibility to early 
CKD in individuals with T2D, possibly mediated by waist 
circumference, blood pressure, and UAE. These research 
findings may improve our understanding the mecha-
nisms to the diabetes-related CKD, especially the genetic 
factors.
Acknowledgement
The authors are grateful to the special research project “Obesi-
dad, Nutricion y Salud” (LE/97), run by the University of Navarra 
(Spain), and to Brazil’s research funding agency, the “Conselho 
Nacional de Desenvolvimento Cientıfico e Tecnológico” (CNPq), 
for the financial support. HHM Hermsdorff is a CNPq Research 
Productivity Fellow.
Statement of Ethics
This study was approved by the Hospital de Clínicas de Porto 
Alegre Ethics Board (2015.0625), and all of the participants pro-
vided written informed consent.
Conflict of Interest Statement
The authors have no conflicts of interest to declare.
Funding Sources
This work was supported by the FIPE – Fundo de Incentivo à 
Pesquisa do Hospital de Clínicas de Porto Alegre. The work was 
also financially supported by the Conselho Nacional de Desen-
volvimento Científico e Tecnológico’ (CNPq; Brazil). T.S. was a 
recipient of a CNPq scholarship.
Author Contributions
Júlia Marchetti: conceptualization, methodology, formal anal-
ysis, data curation, and writing – the original draft; Karla P. Albino: 
formal analysis, writing – review and editing; Helen Hermana and 
M. Hermsdorff: conceptualization, methodology, formal analysis, 
supervision, and writing – review and editing; Leidjaira L Juvan-
hol: formal analysis; José Alfredo Martinez: data curation and writ-
ing – review and editing; Thais Steemburgo: conceptualization, 
formal analysis, data curation, supervision, and writing – the orig-
inal draft.





 1 American Diabetes Association. 7. Diabetes 
technology: standards of medical care in dia-
betes-2020. Diabetes Care. 2020; 43(Suppl 1): 
S77–52.
 2 Tuttle KR, Bakris GL, Bilous RW, Chiang JL, 
Boer IH, Goldstein-Fuchs J, et al. Diabetic 
kidney disease: a report from an ADA Con-
sensus Conference. Diabetes Care. 2014; 37: 
2864–83.
 3 Afkarian M, Zelnick LR, Hall YN, Heagerty 
PJ, Tuttle K, Weiss NS, et al. Clinical manifes-
tations of kidney disease among US adults 
with diabetes, 1988–2014. JAMA. 1988-
20142016; 316: 602–10.
 4 De Boer IH; DCCT/EDIC Research Group. 
Kidney disease and related findings in the Di-
abetes Control and Complications Trial/Epi-
demiology of Diabetes Interventions and 
Complications study. Diabetes Care. 2014; 
37(1): 24–30.
 5 Wu Y, Ding Y, Tanaka Y, Zhang W. Risk fac-
tors contributing to type 2 diabetes and recent 
advances in the treatment and prevention. Int 
J Med Sci. 2014; 11: 1185–200.
 6 Sladek R, Rocheleau G, Rung J, Dina C, Shen 
L, Serre D, et al. A genome-wide association 
study identifies novel risk loci for type 2 dia-
betes. Nature. 2007; 445: 881–5.
 7 Li H, Kilpeläinen TO, Liu C, Zhu J, Liu Y, Hu 
C, et al. Association of genetic variation in 
FTO with risk of obesity and type 2 diabetes 
with data from 96,551 East and South Asians. 
Diabetologia. 2012; 55: 981–95.
 8 Fawwad A, Siddiqui IA, Basit A, Zeeshan NF, 
Shahid SM, Nawab SN, et al. Common variant 
within the FTO gene, rs9939609, obesity and 
type 2 diabetes in population of Karachi, Pak-
istan. Diabetes Metab Syndr. 2015; 10: 43–7.
 9 Yang Y, Liu B, Xia W, Yan J, Liy H, Hu L, et 
al. FTO genotype and type 2 diabetes mellitus: 
spatial analysis and meta-analysis of 62 case-
control studies from different regions. Genes. 
2017; 8(2): 70.
10 Hubacek JA, Viklicky O, Dlouha D, Bloudicko-
vam S, Kubinova R, Peasey A, et al. The FTO 
gene polymorphism is associated with end-
stage renal disease: two large independent 
case–control studies in a general population. 
Nephrol Dial Transplant. 2012; 27: 1030–5.
11 Taira M, Imamura M, Takahashi A, Kamatani 
Y, Yamauchi T, Araki S, et al. A variant with-
in the FTO confers susceptibility to diabetic 
nephropathy in Japanese patients with type 2 
diabetes. PLoS One. 2018; 13(12): e0208654.
12 Osman WM, Jelinek HF, Tay GK, Hassan 
MH, Almahmeed W, Khandoker AH, et al. 
Genetics of diabetic kidney disease: a follow-
up study in the Arab population of the United 
Arab Emirates. Mol Genet Genomic Med. 
2019; 7(12): e985.
13 Gerken T, Girard CA, Tung Y-CL, Webby CJ, 
Saudek V, Hewitson KS, et al. The obesity-as-
sociated FTO gene encodes a 2-oxoglutarate-
dependent nucleic acid demethylase. Science. 
2007; 318(5855): 1469–72.
14 Hardy R, Wills AK, Wong A, Elks CE, Ware-
ham NJ, Loos RJF, et al. Life course variations 
in the associations between FTO and MC4R 
gene variants and body size. Hum Mol Genet. 
2010; 19(3): 545–52.
15 Olszewski PK, Fredriksson R, Olszewska AM, 
Stephansson O, Alsio J, Radomska KJ, et al. 
Hypothalamic FTO is associated with the reg-
ulation of energy intake not feeding reward. 
BMC Neurosci. 2009; 10: 129.
16 Loos RJ, Yeo GS. The bigger picture of FTO: 
the first GWAS-identified obesity gene. Nat 
Rev Endocrinol. 2014; 10(1): 51–61.
17 Pausova Z, Syme C, Abrahamowicz M, Xiao 
Y, Leonard GT, Perron M, et al. A common 
variant of the FTO gene is associated with not 
only increased adiposity but also elevated 
blood pressure in French Canadians. Circ 
Cardiovasc Genet. 2009; 2: 260–9.
18 Freathy RM, Timpson NJ, Lawlor DA, Xiao Y, 
Leonard GT, Perron M, et al. Common varia-
tion in the FTO gene alters diabetes-related 
metabolic traits to the extent expected given 
its effect on BMI. Diabetes. 2008; 57: 1419–26.
19 Kazancioğlu R. Risk factors for chronic kid-
ney disease: an update. Kidney Int Suppl 
(2011). 2013; 3: 368–71.
20 National Kidney Foundation. K/DOQI clini-
cal practice guidelines for chronic kidney dis-
ease: evaluation, classification and stratifica-
tion. Am J Kidney Dis. 2002; 39(Suppl 1): S1–
266.
21 Steemburgo T, Azevedo MJ, Gross JL, Mila-
gro F, Campion J, Martinez JA. The rs7204609 
polymorphism in the Fat Mass and Obesity-
Associated gene is positively associated with 
central obesity and microalbuminuria in pa-
tients with type 2 diabetes from Southern Bra-
zil. J Ren Nutr. 2012; 22(2): 228–36.
22 Molitch ME, DeFronzo RA, Franz MJ, Keane 
WF, Mogensen CE, Parving H, et al. Ne-
phropathy in diabetes. Diabetes Care. 2004; 
27(Suppl 1): S79–83.
23 Alberti KG, Eckel RH, Grundy SM, Zimmet 
PZ, Cleeman JI, Donato KA, et al. Harmoniz-
ing the metabolic syndrome. Circulation. 
2009; 120(16): 1640–5.
24 Whelton PK, Carey RM, Aronow WS, Casey 
DE, Collina KJ, Himmelfarb CD, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/
APhA/ASH/ASPC/NMA/PCNA guideline 
for the prevention, detection, evaluation, and 
management of high blood pressure in adults: 
a report of the American College of Cardiol-
ogy/American Heart Association Task Force 
on Clinical Practice Guidelines. J Am Coll 
Cardiol. 2018; 71: e127–248.
25 Camargo JL, Lara GM, Wendland AE, Gross 
JL, De Azevedo MJ. Agreement of different 
immunoassays for urinary albumin measure-
ment. Clin Chem. 2008; 54: 925–7.
26 Gross JL, Azevedo MJ, Silveiro SP, Canani 
LH, Caramori ML, Zelamnovitz T. Diabetic 
nephropathy:  diagnosis, prevention, and 
treatment. Diabetes Care. 2005; 28: 164–76.
27 Levey AS, Stevens LA, Schmid CH, Zhang Y, 
Castr AF, Feldman HI, et al. A new equation 
to estimate glomerular filtration rate. Ann In-
tern Med. 2009; 150: 604–12.
28 Bentler PM, Stein JA. Structural equation 
models in medical research. Stat Methods 
Med Res. 1992; 1(2): 159–81.
29 Gamborg M, Andersen PK, Baker JL, Budtz-
Jorgensen E, Jensen G, Sorensen TI. Life 
course path analysis of birth weight, child-
hood growth, and adult systolic blood pres-
sure. Am J Epidemiol. 2009; 169: 1167–78.
30 Kline RB. Principles and practice of structural 
equation modeling. New York:  Guilford 
Press; 2004. Vol. 2.
31 Hair JF, Black WC, Babin BJ, Anderson RE, 
Tatham RL. Análise multivariada de dados. 
6th ed. Porto Alegre: Bookman; 2009.
32 Hu LT, Bentler PM. Cutoff criteria for fit in-
dexes in covariance structure analysis: con-
ventional criteria versus new alternatives. 
Struct Equ Model. 1999; 6(1): 1–55.
33 Hooper D, Coughlan J, Mullen M. Structural 
equation modeling: guidelines for determin-
ing model fit. J Business Res Methods. 2008; 6: 
53–60.
34 Baltar VT, Xun WW, Johansson M, Ferrari P, 
Chuang S, Relton C, et al. A structural equa-
tion modelling approach to explore the role of 
B vitamins and immune markers in lung can-
cer risk. Eur J Epidemiol. 2013; 28: 677–88.
35 Thomas MC, Brownlee M, Suszlak K, Sharma 
K, Jandeleit-Dahm KA, Zoungas S, et al. Dia-
betic kidney disease. Nat Rev Dis Primers. 
2015; 1: 15018.
36 Wickman C, Kramer H. Obesity and kidney 
disease:  potential mechanisms. Semin 
Nephrol. 2013; 33: 14–22.
37 Da Silva PM, Carvalho D, Nazare J, Martins 
L, Aguiar C, Manso MC, et al. Prevalence of 
microalbuminuria in hypertensive patients 
with or without type 2 diabetes in a Portu-
guese primary care setting: the RACE (Micro-
albumin Screening Survey) study. Rev Port 
Cardiol. 2015; 34(4): 237–46.
38 Lee YY, Yang CK, Weng YM, Chuang CH, Yu 
W, Chen JC, et al. All components of meta-
bolic syndrome are associated with microal-
buminuria in a Chinese population. PLoS 
One. 2016; 11(6): e0157303.
39 Bonnet F, Marre M, Halimi JM, Stengel B, 
Lange C, Laville M, et al. Waist circumference 
and the metabolic syndrome predict the de-
velopment of elevated albuminuria in non-
diabetic subjects: the DESIR Study. J Hyper-
tens. 2006; 24: 1157–63.
40 Phani NM, Vohra M, Rajesh S, Adhikari P, 
Nagri SK, D’Souza SC, et al. Implications of 
critical PPARγ2, ADIPOQ and FTO gene 
polymorphisms in type 2 diabetes and obesi-
ty-mediated susceptibility to type 2 diabetes 
in an Indian population. Mol Genet Genom-





41 Speakman JR. The “Fat Mass and Obesity Re-
lated” (FTO) gene: mechanisms of impact on 
obesity and energy balance. Curr Obes Rep. 
2015; 4(1): 73–91.
42 Frayling TM, Timpson NJ, Weedon MN, Zeg-
gini E, Freathy RM, Lindgren CM, et al. A 
common variant in the FTO gene is associated 
with body mass index and predisposes to 
childhood and adult obesity. Science. 2007; 
316: 889–94.
43 Sjogren M, Lyseenko V, Jonsson A, Berglund 
G, Nilsson P, Groop L, et al. The search for 
putative unifying genetic factors for compo-
nents of the metabolic syndrome. Diabetolo-
gia. 2008; 51: 2242–51.
44 Hotta K, Nakata Y, Matsuo T, Kamhara S, Ko-
tani K, Komatsu R, et al. Variations in the 
FTO gene are associated with severe obesity 
in the Japanese. J Hum Genet. 2008; 53: 546–
53.
45 Adeyemo A, Chen G, Zhou J, Shriner D, Dou-
matey A, Huang H, et al. FTO genetic varia-
tion and association with obesity in West Af-
ricans and African Americans. Diabetes. 
2010; 59: 1549–54.
46 Silva RC, Silva DA, Bastos JL, Peres KG, Gon-
zales-Chica DA. Anthropometric measures 
change and incidence of high blood pressure 
levels among adults: a population-based pro-
spective study in Southern Brazil. J Hyper-
tens. 2017; 35(1): 39–46.
47 Feng RN, Zhao C, Wang C, Niu Y, Li K, Guo 
F, et al. BMI is strongly associated with hyper-
tension, and waist circumference is strongly 
associated with type 2 diabetes and dyslipid-
emia, in northern Chinese adults. J Epidemi-
ol. 2012; 22: 317–23.
48 Fujita M, Sato Y, Nagashima K, Takahashi S, 
Hata A. Predictive power of a body shape in-
dex for development of diabetes, hyperten-
sion, and dyslipidemia in Japanese adults: a 
retrospective cohort study. PLoS One. 2015; 
10: e0128972.
49 Emdin CA, Rahimi K, Neal B, Callender T, 
Perkovic V, Patel A. Blood pressure lowering 
in type 2 diabetes: a systematic review and 
meta-analysis. JAMA. 2015; 313(6): 603–15.
50 Boussageon R, Bejan-Angoulvant T, Saada-
tian-Elahi M, Lafont S, Bergeonneau C, Kas-
sai B, et al. Effect of intensive glucose lowering 
treatment on all-cause mortality, cardiovas-
cular death, and microvascular events in type 
2 diabetes: meta-analysis of randomised con-
trolled trials. BMJ. 2011; 343: d4169.
51 Thompson JE, Smith W, Ware LJ, Mels 
CMC, Van Rooyen JM, Huisman HW, et al. 
Masked hypertension and its associated car-
diovascular risk in young individuals: the Af-
rica-PREDICT study. Hypertens Res. 2016; 
39: 158–65.
52 Heerspink HJ, Kröpelin TF, Hoekman J, de 
Zeeuw D, Rooyen JM, Huisman HW, et al. 
Drug-induced reduction in albuminuria is as-
sociated with subsequent renoprotection: a 
meta-analysis. J Am Soc Nephrol. 2015; 26(8): 
2055–64.
53 Gheith O, Farouk N, Nampoory N, Halim 
MA, Al-Otaibi T. Diabetic kidney disease: 
worldwide difference of prevalence and risk 
factors. J Nephropharmacol. 2016; 5(1): 49–
56.
54 Alicic RZ, Rooney MT, Tuttle KR. Diabetic 
kidney disease: challenges, progress, and pos-
sibilities. Clin J Am Soc Nephrol. 2017; 12(12): 
2032–45.
